W. Schmitt
The Lancet Oncology · 2012–2019
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Whom W. Schmitt trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Friedrich Leisch (in Artificial Intelligence)
Papers from W. Schmitt's perspective
Ordered by how strongly the researchers W. Schmitt trusts endorse each paper. Same corpus, a different order for every researcher.
- FlexMix: A general framework for finite mixture models and latent class regression in R
- NCBI GEO: archive for functional genomics data sets—10 years on (Nucleic Acids Res.)
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients (Breast Cancer Research and Treatment)
- Reporting recommendations for tumor marker prognostic studies. (Journal of Clinical Oncology)
- Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. (Statistics in Medicine)
- The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. (American Journal of Epidemiology)
- A gene-expression signature as a predictor of survival in breast cancer. (New England Journal of Medicine)
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (Clinical Cancer Research)
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repository (Nucleic Acids Res.)
- NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins (Nucleic Acids Res.)
Their papers
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. (2019) — 601 citations
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. (2018) — 1,800 citations
- Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. (2015) — 942 citations
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization (2012) — 1,152 citations